Eloralintide

Eloralintide (development code LY3841136) is a synthetic analog of amylin, the pancreatic hormone co-secreted with insulin that participates in satiety and gastric-emptying signaling. It is a 37-amino-acid, C-terminally amidated peptide carrying a C20 fatty-diacid lipidation that supports a long-acting profile, with several stabilizing substitutions including a methylene-thioacetal bridge in place of the native disulfide (≈4526 g/mol; CAS 2883634-40-8).

What distinguishes it in the amylin class is receptor selectivity: it is biased toward the AMY1 amylin receptor rather than acting as a dual amylin/calcitonin receptor agonist (DACRA) like cagrilintide. Researchers study this selectivity for its potential to separate satiety effects from calcitonin-receptor-driven activity.

It is popularly discussed in weight-management and metabolic-research circles as a next-generation selective amylin agonist, reputed for strong weight-loss potential with gentler GI tolerability than incretin compounds.

Eloralintide (LY3841136) is a selective amylin receptor agonist popularly discussed for its purported effects on satiety and appetite signaling, with researchers investigating AMY1-receptor-biased agonism as a distinct pathway from the GLP-1 class.

The weight-management community anecdotally associates amylin agonists with meaningful body-weight reduction and follows the compound's phase 2 results and ongoing phase 3 program closely, including combination research alongside incretin agonists like tirzepatide.

These outcomes are the focus of active clinical and preclinical research and intense community interest, and nothing here constitutes medical advice.

In published preclinical work, selective amylin agonism is examined for effects on food intake, body weight, and energy balance in animal models, alongside receptor-pharmacology studies characterizing AMY1 selectivity.

Clinically, a phase 2 trial in adults with obesity or overweight reported dose-dependent body-weight reductions with favorable gastrointestinal tolerability, and a phase 3 program is underway, including combination studies with incretin agonists. Those human trials involve the pharmaceutical development program, not research-grade material; this overview is informational only.

The research compound is supplied as a lyophilized powder and stored at -20°C, sealed and protected from light.

For laboratory work it is reconstituted with bacteriostatic or sterile water like other lipidated metabolic peptides; reconstituted solution is held at 4°C for short-term use or aliquoted and stored at -80°C.